Kim Dongsu, You Dalsan, Jeong In Gab, Hong Jun Hyuk, Ahn Hanjong, Hong Bumsik
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 43 Gil 88, Olympic-Road, Songpa-Gu, 05505, Seoul, Republic of Korea.
J Cancer Res Clin Oncol. 2023 Nov;149(15):13717-13725. doi: 10.1007/s00432-023-05207-x. Epub 2023 Jul 31.
To extend the indications of kidney-sparing surgery (KSS) for ureter cancer by comparing the oncological outcomes between patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU) or KSS.
We retrospectively reviewed 708 patients with UTUC who underwent RNU (N = 646) or KSS (N = 62) between 2011 and 2019 to analyze the oncologic outcomes and prognostic factors. Subgroup analyses were performed for patients with unifocal ureteral urothelial carcinoma (UC).
No significant difference was observed in the overall survival (OS) or cancer-specific survival (CSS) between RNU and KSS (distal ureterectomy with reimplantation (N = 33), ureterectomy with ileal ureter (N = 14), ureteroscopic tumor resection (N = 10), and ureterectomy with ureteroureterostomy (N = 5)). Among 269 (38.0%) patients with unifocal ureteral UC, 219 and 50 patients underwent RNU and KSS, respectively. OS and CSS were not significantly different between these two groups. Pathologic stage was a significant risk factor in multivariate analysis (hazard ratio = 2.621; p = 0.000). Among 646 RNU patients, 219 (33.9%) had unifocal ureteral UC, 40 (18.3%) with low-grade tumors. Among these, 13 (5.9%) patients with unifocal, low-grade and small (< 2 cm) tumors received nephroureterectomy.
Kidney-sparing surgery should be regarded as an important alternative to RNU for patients with unifocal ureteral UC thought to have noninvasive disease to preserve renal function and reduce overtreatment.
通过比较接受根治性肾输尿管切除术(RNU)或保留肾单位手术(KSS)的上尿路尿路上皮癌(UTUC)患者的肿瘤学结局,扩大保留肾单位手术(KSS)治疗输尿管癌的适应证。
我们回顾性分析了2011年至2019年间接受RNU(N = 646)或KSS(N = 62)的708例UTUC患者,以分析肿瘤学结局和预后因素。对单灶性输尿管尿路上皮癌(UC)患者进行亚组分析。
RNU组和KSS组(输尿管远端切除术加再植术(N = 33)、回肠代输尿管输尿管切除术(N = 14)、输尿管镜肿瘤切除术(N = 10)和输尿管输尿管吻合术输尿管切除术(N = 5))的总生存期(OS)或癌症特异性生存期(CSS)无显著差异。在269例(38.0%)单灶性输尿管UC患者中,分别有219例和50例接受了RNU和KSS。两组的OS和CSS无显著差异。病理分期在多因素分析中是一个显著的危险因素(风险比=2.621;p = 0.000)。在646例RNU患者中,219例(33.9%)患有单灶性输尿管UC,其中40例(18.3%)为低级别肿瘤。其中,13例(5.9%)单灶、低级别且肿瘤较小(<2 cm)的患者接受了肾输尿管切除术。
对于被认为患有非侵袭性疾病的单灶性输尿管UC患者,保留肾单位手术应被视为RNU的重要替代方案,以保留肾功能并减少过度治疗。